Loading…
Employees: 1,197
Size Shanghai Kaibao Pharmaceutical (300039.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $756M, the 2887th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.82 on 6 Nov 2026.
Performance Over six months the shares fell 16.6%, against -19.4% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 14.4% over the last twelve months (peer median +0.5%); the operating margin is 22.4% (peer median 6.8%).
Valuation It trades at 3.7× enterprise value to sales against a peer median of 3.0× (7th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points above its cost of capital (5.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.00B | CN¥1.14B | CN¥1.46B | CN¥1.57B | CN¥1.10B |
| Revenue growth | — | -22% | -8% | +43% | — |
| Gross profit | CN¥814M | CN¥896M | CN¥1.16B | CN¥1.24B | CN¥845M |
| EBITDA | n/a | CN¥301M | CN¥389M | CN¥347M | CN¥213M |
| Net income | CN¥235M | CN¥279M | CN¥376M | CN¥328M | CN¥191M |
| Free cash flow | CN¥192M | CN¥295M | CN¥165M | CN¥365M | CN¥348M |
| Capital expenditure | CN¥20.1M | CN¥27.0M | CN¥141M | CN¥29.1M | CN¥31.6M |
| Total debt | CN¥4.11M | CN¥6.19M | CN¥7.74M | CN¥4.29M | CN¥9.10M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300039.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | -8.4% | 9th highest of 21 |
| 6-month return | -16.6% | -19.4% | 10th highest of 21 |
| Distance from 52-week high | -28.8% | -39.3% | 4th highest of 21 |
| Revenue growth (TTM) | -14.4% | +0.5% | 4th lowest of 20 |
| Operating margin | 22.4% | 6.8% | 4th highest of 19 |
| EV / Sales | 3.7× | 3.0× | 7th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 1.8% | 4.9% | 3rd least demanding of 12 |
| Growth delivered (Del g) | +4.8% | +12.1% | 2nd lowest of 12 |
| Hurdle (Req g minus delivered) | -3.0 pp | -4.0 pp | 6th most demanding of 12 |
| ROIC minus cost of capital | +0.4 pp | -0.2 pp | 9th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | 3.7× | 1.8% | +4.8% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 1.6× | 14.7% | +15.6% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | n/a | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | 1.6× | 4.9% | +13.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | 2.5× | 3.6% | -1.3% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | 2.0× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 5.1× | 4.0% | +18.5% |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | 2.1× | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 5.2× | n/a | n/a |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 5.0× | 25.8% | +13.4% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 4.1× | 20.4% | +12.1% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 2.3× | n/a | n/a |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | 3.6× | 24.3% | +6.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | 3.4× | 3.0% | +7.0% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | 10.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 3.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | n/a | n/a | n/a |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 1.0× | 1.5% | +7.9% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 5.1× | 14.1% | +62.3% |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | 2.1× | -14.7% | +8.9% |